Perspective Therapeutics reports FY2025 net loss $103M; lead program shows durable responses; cash ~$309M post-offering

Perspective Therapeutics, Inc.

Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).
Cash $145M at Dec 31, 2025; Feb 2026 equity offering net proceeds ~$164M; runway into late 2027.
VMT-α-NET: 76% progression-free at ~13 weeks additional follow-up; 39% objective response rate in Cohort 2.
Cohort 3 cleared for more patients; all Cohort 2 expected to have ≥48 weeks follow-up by mid-2026.
$10M non-cash impairment for deprioritized preclinical asset; three clinical programs continue.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025 and providing recent business highlights.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000728387-26-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.